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Abstract
Background: Inflammation is a key factor in the process of carcinogenesis from chronic gastritis induced by Helicobacter
pylori. Selenoprotein S (SEPS1) is involved in the control of the inflammatory response in the endoplasmic reticulum (ER).
Recently the -105G>A polymorphism in the promoter of SEPS1 was shown to increase pro-inflammatory cytokine
expression. We examined the association between this polymorphism and the risk of gastric cancer.
Methods: We took stomach biopsies during endoscopies of 268 Japanese gastric cancer patients (193 males and 75
females, average age 65.3), and 306 control patients (184 males and 122 females, average age 62.7) and extracted the
DNA from the biopsy specimens. All subjects provided written informed consent. For the genotyping of the SEPS1
promoter polymorphism at position -105G>A, PCR-RFLP methods were used and the PCR products were digested with
PspGI.
Logistic-regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CI), adjusting for age,
sex, and H. pylori infection status.
Results: Among cases, the distribution of genotypes was as follows: 88.4% were GG, 11.2% were GA, and 0.4% were
AA. Among controls, the distribution was as follows: 92.5% were GG, 7.2% were GA, and 0.3% were AA. Among males,
carrying the A allele was associated with an increased odds of gastric cancer, compared with the GG genotype (OR: 2.0,
95% CI 1.0–4.1, p = 0.07). Compared with the GG genotype, carrying the A allele was significantly associated with
increased risks of intestinal type gastric cancer (OR: 2.0, 95%CI 1.0–3.9, p < 0.05) as well as of gastric cancer located in
the middle third of the stomach (OR: 2.0, 95%CI 1.0–3.9, p < 0.05).
Conclusion: The -105G>A promoter polymorphism of SEPS1 was associated with the intestinal type of gastric cancer.
This polymorphism may influence the inflammatory conditions of gastric mucosa. Larger population-based studies are
needed for clarifying the relation between inflammatory responses and SEPS1 polymorphism.
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Background
Gastric cancer remains a considerable public health prob-
lem worldwide. Although the incidence and mortality
rates of gastric cancer have decreased gradually, gastric
cancer is second only to lung cancer as the leading cause
of cancer death around the world [1,2]. Helicobacter pylori
(H. pylori) was designated as a causative pathogen for gas-
tric carcinogenesis[3]. Inflammation may be a key factor
in the process of carcinogenesis from chronic gastritis
induced by H. pylori[4]. However, only a small number of
infected patients actually develop gastric cancer. This sug-
gests that host genetic factors, such as genes associated
with inflammatory responses, may also play an important
role in stomach carcinogenesis.
Selenoprotein S (SEPS1, also known as SelS, SELENOS,
VIMP) is a novel selenoprotein located in the endoplas-
mic reticulum (ER) and the plasma membrane. It is
involved in the control of the inflammatory response in
ER[5].
SEPS1 protects cells from oxidative damage and apopto-
sis, and is widely expressed in a variety of tissues [6-8].
Recently, the -105G>A promoter polymorphism of SEPS1
was shown to be strongly associated with plasma levels of
pro-inflammatory cytokines, such as interleukin 1 beta
(IL-1β), interleukin 6 (IL-6) and tumor necrosis factor
alpha (TNF-α). The -105G>A promoter polymorphism of
SEPS1 may affect SEPS1 mRNA levels[9]. The substitution
of the A allele for the G allele at position -105 reduced the
promoter activity in HepG2 cells[10].
After the report of a polymorphism in the SEPS1 promoter
region, some clinical studies have shown associations
between the SEPS1 polymorphism with coronary heart
disease and ischemic stroke[11] and preeclampsia[12],
while other studies reported no associations between this
variant with inflammatory bowel disease[13] or cerebrov-
ascular disease[14].
However, the association between the -105G>A promoter
polymorphism of SEPS1 and gastric cancer risk has not yet
been studied.
IL-1β levels have been associated with gastric cancer[15],
and because the SEPS1 polymorphism affects the levels of
IL-1β, the SEPS1 polymorphism may be an important
genetic factor for the development of gastric cancer.
In this case-control study, we examined the associations
between the SEPS1 promoter polymorphism and both the
gastric cancer risk and the inflammatory responses in gas-
tric mucosa as measured in gastric biopsy samples.
Methods
Patients and Controls
The study included patients who received an upper gas-
trointestinal endoscopy at the Fujita Health University
Hospital in Japan. Consecutively enrolled subjects were
screened for gastric cancer by upper gastrointestinal
endoscopy followed by a barium X-ray examination.
Cases were 268 Japanese patients (193 males, 75 females,
average age 65.3 ± 12.0 years) who were diagnosed with
primary gastric cancer, and controls were 306 people (184
males, 122 females) without gastric cancer who also
underwent upper gastrointestinal endoscopy. Gastric can-
cer was diagnosed histologically at the Pathology Division
of our hospital, and cancers was classified according to
Lauren' s classification[16]. The cancer staging and ana-
tomic location information were also obtained. Patients
with systemic diseases and malignancies in other organs,
or who had received non-steroidal anti-inflammatory
drugs were excluded.
The Ethical Committee of the School of Medicine at Fujita
Health University approved the protocol. Written
informed consent was obtained from each study partici-
pant.
Histological study and DNA Extraction
Gastric biopsy specimens were taken from the non-can-
cerous mucosa in the antrum and the greater curvature of
the stomach, using an upper gastrointestinal scope. Some
parts of each specimen were fixed in 10% buffered forma-
lin and embedded in paraffin, while the other parts were
immediately frozen and stored at -80°C until DNA extrac-
tion. All histological diagnoses were made at the Division
of Pathology of our hospital. The severity of chronic gas-
tritis was classified by a pathologist who did not have
access to any clinical information, according to the
updated Sydney system[17] with each factor being scored
from 0 (normal) to 3 (marked).
The genomic DNA was extracted from stored samples at -
80°C using proteinase K and DNA extraction kits (Quia-
gen, Valencia, CA).
Polymorphism Analysis of SEPS1 Gene
The genotype for the SEPS1 promoter region at position -
105 was determined using PCR-based restriction fragment
length polymorphisms (PCR-RFLP). We used primers that
included the SEPS1 (-105) polymorphism area. Subse-
quently, the identification was done after PCR-amplifica-
tion, using the following primers 5'-
AAATCCGTGAACGAGGTCCG-3'and 5'-GAG-
CAACTAATCTGAATCAGG-3'. PCR was carried out with
0.1 μg of genomic DNA in a volume of 20 μL. The DNA
was denatured at 94°C for 5 minutes, followed by 35
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72°C for 40 seconds, with a final extension at 72°C for 7
minutes. The PCR reactions were done using Blend Taq
(Toyobo Co., Ltd., Osaka, Japan). The amplified PCR
products were digested overnight with 5 units of PspGI
(New England BioLabs, Inc., Beverly, MA, USA) at 75°C.
Subsequently, the digested products were analyzed on 3%
agarose gels. These gels were stained with ethidium bro-
mide (0.5 μg/mL), and the genotypes were determined by
analyses of different bands. The presence of a PspGI site
was indicated by the cleavage of the 324 bp amplified
product to yield fragments of 179 and 145 bp. Genotyp-
ing was confirmed by direct sequencing in a few randomly
selected samples.
Detection of H. pylori
H. pylori positivity was determined by microscopic exam-
ination, urea breath test, or serum anti-HP antibody titers.
Infection was diagnosed when at least one of these tests
was positive.
Statistical Analysis
Hardy-Weinberg equilibrium of the SEPS1 gene allele in
the controls and gastric cancer patients were assessed by χ2
statistics. Clinical characteristics between patients with or
without gastric cancer, and differences in gastritis scores
between A carriers and G/G were examined by the Mann-
Whitney U test. Logistic-regression analysis was used to
estimate odds ratios (OR) and 95% confidence intervals
(CI) for the genotypes, with adjustment for age, sex, and
H. pylori infection status. A p-value < 0.05 was considered
statistically significant.
Results
Characteristics of the subjects
The characteristics of the cases and controls are summa-
rized in Table 1. H. pylori infection and age were higher in
gastric cancer patients than in controls (p < 0.05).
The main endoscopic findings for the control group were:
gastric ulcer in 68 patients (22.2%), duodenal ulcer in 35
(11.4%), gastric and duodenal ulcer in 5 (1.7%), and gas-
tritis in 198(64.7%).
Distribution of the SEPS1 genotypes
Table 2 shows the genotype frequencies of SEPS1 in
patients with gastric cancer and the control group. The
polymorphism at position -105 of SEPS1 was typed in all
574 subjects. Among cases, the distribution of genotypes
was as follows: 88.4% were GG, 11.2% were GA, and
0.4% were AA. Among controls, the distribution was as
follows: 92.5% were GG, 7.2% were GA, and 0.3% were
AA (Table 2). The frequency of SEPS1 polymorphism in
the controls and gastric cancer patients did not deviate sig-
nificantly from those expected under the Hardy-Weinberg
equilibrium (p = 0.42, 0.96 respectively). Among males,
compared with the GG genotype, the genotypes GA and
AA combined was associated with an increased odds of
gastric cancer (OR: 1.97, 95% CI 0.95–4.06, p = 0.067;
Table 3).
In additional analyses, the associations between the
SEPS1 polymorphism and clinicopathologic features of
gastric cancer, such as the tumor location, stage, and Lau-
ren's histological classification, were evaluated. Carrying a
-105 A allele was significantly associated with increased
risks of Lauren's intestinal type of gastric cancer (OR: 1.99,
95%CI 1.01–3.93, p < 0.05) and of gastric cancer located
in middle third part of the stomach (OR: 2.01, 95%CI
1.03–3.92, p < 0.05) (Table 4).
Among 301 H. pylori-positive subjects, the neutrophil
infiltration, mononuclear cell infiltration, the atrophy
and metaplasia scores of the antral mucosa showed no sig-
nificant differences between the -105 A allele carriers and
subjects homozygous for the G allele (data not shown).
Among controls, there were no significant genotype differ-
ences among the patients with gastric ulcer, duodenal
ulcer, and gastritis (data not shown).
Discussion
In this study of a Japanese population, we have demon-
strated for the first time that the -105G>A polymorphism
of SEPS1 gene was associated with increased risks of intes-
tinal type of gastric cancer and gastric cancer located in
middle third part of the stomach. Although low selenium
status has been associated with risk of human gastric can-
cer [18,19], and high selenium diet inhibit the growth of
H. pylori in Guinea pigs [20], human clinical trials have
failed to demonstrate a benefit for selenium supplements
in the prevention of precancerous gastric lesions [21]. The
-105G>A promoter polymorphism, which is located in an
ER stress response element of the seps1 gene coding for
SEPS1, was strongly associated with circulating levels of
pro-inflammatory cytokines, such as IL-1b, IL-6, and TNF-
a, and with SEPS1 gene expression levels in humans[9].
The phenotypic consequences of this -105G>A polymor-
phism have been investigated in some diseases related to
chronic inflammation [11-14]. The results have been
Table 1: Characteristics of subjects
GC Controls P
number 268 306
males/females 193/75 184/122 N.S.
Average age (± SD) 65.3 ± 12.0 62.7 ± 13.2 < 0.05a
HP positive rate (%) 86.2 68.0 < 0.05a
GC: gastric cancer, HP: Helicobacter pylori
aGC vs. Controls, Mann-Whitney U test.BMC Gastroenterology 2009, 9:2 http://www.biomedcentral.com/1471-230X/9/2
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inconsistent. One study in Finnish cohort showed the
relation of other SEPS1 SNPs and coronary heart disease
or ischemic stroke event[11], and one report in a large
Norwegian case-control cohort showed the A allele of the
SEPS1-105G>A polymorphism is a significant risk factor
for preeclampsia[12]. On the other hand, one report in
Germany showed the SELS-105G>A polymorphism was
not associated with IBD susceptibility and did not con-
tribute to a certain disease phenotype or increased TNF-
alpha levels in IBD patients[13]. Also one report showed
non-significant differences of SEPS1 allele frequencies
between young stroke patients and healthy controls from
Italy and Germany[14].
In our study, there was no association overall between the
-105G>A variant and gastric cancer. However, in detailed
clinicopathological analysis, we found significant associa-
tions between carrying the A allele and the odds of specific
types of gastric cancer, with adjustment for age, sex, and
H. pylori infection status. We have 74 healthy volunteer
DNA (all are H. pylori negative). We examined these DNA
about SEPS1 polymorphism -105G>A. As a result, the
numbers of GG were 70, the numbers of GA were 4 and
none of them was AA. From these results, we thought our
comparison between gastric cancer patients and non gas-
tric cancer patients was proper comparison for analyzing
the association risk of gastric cancer and SEPS1 polymor-
phism other than the association of H. pylori.
The carcinogenic pathway for the intestinal type of gastric
cancer mainly involves H. pylori infection. The infection
causes inflammation and tissue regeneration, and these
processes cause the deviation from the normal pathway of
gastric differentiation to precancerous states[4,22]. It has
been suggested that the SEPS1 polymorphism may be
involved in the pathway from chronic gastric inflamma-
tion to carcinogenesis. However, the AA genotype is very
rare in the Japanese population, and thus, definite conclu-
sions about the genotype-phenotype correlations of
homozygous carriers of this SEPS1 promoter polymor-
phism can only be drawn from larger studies involving
multiple hospital centers.
Among males, the SEPS1 -105A allele carriers had
increased odds of gastric cancer compared with those with
the GG genotype. There is one report showing gender-spe-
cific associations of the SEPS1 polymorphism with coro-
nary heart disease[11]. The authors of the study found
relations between a polymorphism in another region of
the SEPS1 gene and coronary heart disease risk in females.
They suspected that the gender-specific associations with
SEPS1 SNP were due to differences in disease etiology or
in the hormonal milieu for men and women [11]. In epi-
demiological studies, gender has also been related to gas-
tric cancer [23,24]. These epidemiological findings are
consistent with the gender specific association between
the -105G>A polymorphism and gastric cancer.
Based on the reports of the consequences of impaired
SEPS1 gene expression and of the SEPS1 -105G>A poly-
morphism being functionally involved in inflammatory
responses[9], we further assessed gastritis scores in the
non-cancerous areas of the antrum in H. pylori positive
patients. However, we did not find significant differences
between SEPS1 -105GG homozygotes and -105A allele
carriers (data not shown). It is possible that the number of
cases for this analysis were relatively low. Also, this inves-
tigation was not a direct comparison of inflammatory
Table 2: SEPS1 polymorphism and GC risk
genotypes patients with GC
n (%)
control patients
n (%)
OR (95%CI) P
G/G 237 (88.4) 283 (92.5) reference
G/A 30 (11.2) 22 (7.2) 1.66 (0.91–3.01) 0.097
A/A 1 (0.4) 1 (0.3) 0.77 (0.05–12.44) 0.852
G/A+A/A 31 23 1.61 (0.90–2.89) 0.112
GC: gastric cancer, CI: confident interval
Table 3: Association between SEPS1 polymorphism and gender
genotype G/G vs. G/A+A/A
G/G G/A A/A OR (98%CI) P
Control patients male 171 12 1 reference
female 112 10 0
GC patients male 169 23 1 1.97(0.95–4.06) 0.067
female 68 7 0 1.17(0.42–3.23) 0.764
GC: gastric cancer, CI: confident intervalBMC Gastroenterology 2009, 9:2 http://www.biomedcentral.com/1471-230X/9/2
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cytokine levels by genotypes of this polymorphism as has
been reported in the literature[9]. Therefore, the exact role
of selenoproteins in gastric carcinogenesis and inflamma-
tion has not yet been determined. Previous reports have
found associations between cytokines and gastric can-
cer[15,25]. In future studies, the analysis of these inflam-
matory cytokines in gastric cancer will be useful for
understanding the mechanisms of carcinogenesis in the
stomach.
Conclusion
In conclusion, carrying an A allele at the SEPS1 -105G>A
polymorphism is a risk factor for the intestinal type of gas-
tric cancer and gastric cancer located in the middle third
of the stomach in a Japanese population. The A allele may
be contributing to gastric cancer by influencing the
inflammatory response to H. pylori infection in the stom-
ach. Further studies in larger cohorts of gastric cancer may
be needed to investigate the actual role of SEPS1 and the
important implications of genetic alterations of the
selenoproteins in chronic inflammatory responses and
carcinogenesis in the stomach.
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